Unresectable, Recurrent, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300) (NCT02625623) | EMD Serono Research & Development Institute, Inc. | 2015-12-28 |
Track Unresectable, Recurrent, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma automatically
Every clearance here is in the API, with alerts when new ones post.